1,374 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Novartis' CTL109 BLA Gets Priority Review Status from FDA http://www.zacks.com/stock/news/254719/novartis-ctl109-bla-gets-priority-review-status-from-fda?cid=CS-ZC-FT-254719 Mar 30, 2017 - Novartis A.G. (NVS) announced that the FDA has accepted and granted priority review designation to its biologics license application (BLA) for pipeline candidate, CTL019 (tisagenlecleucel-T).
AEGON NV: It's Closing Time For This Preferred Stock https://seekingalpha.com/article/4058629-aegon-nv-closing-time-preferred-stock?source=feed_sector_financial Mar 28, 2017 - AEB has reached levels where the upside potential is limited by its fundamentals.Floating Rate preferred stocks have had a good year so far, but at some point it is wise to cash in.There are other opt
Leucadia National Buys Lonestar Resources US, NXP Semiconductors NV, Deutsche Bank AG, Sells ... http://www.gurufocus.com/news/495759/leucadia-national-buys-lonestar-resources-us-nxp-semiconductors-nv-deutsche-bank-ag-sells-procter--gamble-co-coty-spdr-sp-500 Mar 27, 2017 - Leucadia National Buys Lonestar Resources US, NXP Semiconductors NV, Deutsche Bank AG, Sells Procter & Gamble Co, Coty, SPDR S&P 500, Stocks: LONE,NXPI,DB,LVLT,JNS,TLT,SINA,SPY,WR,PG,COTY,GLD,, release date:Mar 27, 2017
J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe http://www.zacks.com/stock/news/254220/jj-jnj-anaemia-drug-marketing-label-expanded-in-europe?cid=CS-ZC-FT-254220 Mar 27, 2017 - Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).
TiGenix NV (ADS) (TIG) Presents At Deutsche Bank Depositary Receipts Virtual Investor Conference - Slideshow https://seekingalpha.com/article/4057764-tigenix-nv-ads-tig-presents-deutsche-bank-depositary-receipts-virtual-investor-conference?source=feed_sector_healthcare Mar 24, 2017 - The following slide deck was published by TiGenix NV (NYSE:ADS) in conjunction with this event.
The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial http://www.zacks.com/stock/news/254054/the-zacks-analyst-blog-highlights-milacron-holdings-galapagos-nv-and-raymond-james-financial?cid=CS-ZC-FT-254054 Mar 24, 2017 - The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved http://www.zacks.com/stock/news/253983/pharma-stock-roundup-is-sanofi-buying-flexion-pfizer-merck-kgaa-drug-approved?cid=CS-ZC-FT-253983 Mar 24, 2017 - This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4 http://www.zacks.com/stock/news/253920/aveo-aveo-reports-narrower-than-expected-loss-in-q4?cid=CS-ZC-FT-253920 Mar 23, 2017 - AVEO Pharmaceuticals, Inc. (AVEO) reported a narrower-than-expected loss in the fourth-quarter 2016.
Bain Capital Investors Llc Buys Frank's International NV, Sells Veritiv http://www.gurufocus.com/news/494454/bain-capital-investors-llc-buys-franks-international-nv-sells-veritiv Mar 22, 2017 - Bain Capital Investors Llc Buys Frank's International NV, Sells Veritiv, Stocks: FI,VRTV,, release date:Mar 22, 2017
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study http://www.zacks.com/stock/news/253764/novartis-acute-heart-failure-drug-fails-in-late-stage-study?cid=CS-ZC-FT-253764 Mar 22, 2017 - Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).
<<<Page 127>